Drugs / GZ389988
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02424942 | Apr 2015 → Jul 2016 | osteoarthritis | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT02845271 | Jul 2016 → Jun 2017 | osteoarthritis | Genzyme, a Sanofi Company | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GZ389988 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02845271 ↗ |
| Action | Inhibit | “Nerve growth factor receptor Trk-A inhibitor” CHEMBL3673452 ↗1“the TrkA Inhibitor, GZ389988” NCT02424942 ↗ |
| Modality | Small molecule | — CHEMBL3673452 ↗ |
| Route | Other | “Route of administration: intraarticular” NCT02424942 ↗ |
| Target | NTRK1 | “Nerve growth factor receptor Trk-A inhibitor” CHEMBL3673452 ↗ |